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Metabolic and inflammatory biomarkers
are associated with epigenetic aging
acceleration estimates in the GOLDN study
Marguerite R. Irvin1*, Stella Aslibekyan1, Anh Do1, Degui Zhi2, Bertha Hidalgo1, Steven A. Claas3,
Vinodh Srinivasasainagendra4, Steve Horvath5,6,7, Hemant K. Tiwari4, Devin M. Absher8 and Donna K. Arnett3
Abstract
Background: Recently, epigenetic age acceleration—or older epigenetic age in comparison to chronological
age—has been robustly associated with mortality and various morbidities. However, accelerated epigenetic aging
has not been widely investigated in relation to inflammatory or metabolic markers, including postprandial lipids.
Methods: We estimated measures of epigenetic age acceleration in 830 Caucasian participants from the Genetics
Of Lipid Lowering Drugs and diet Network (GOLDN) considering two epigenetic age calculations based on differing
sets of 5′-Cytosine-phosphate-guanine-3′ genomic site, derived from the Horvath and Hannum DNA methylation
age calculators, respectively. GOLDN participants underwent a standardized high-fat meal challenge after fasting for
at least 8 h followed by timed blood draws, the last being 6 h postmeal. We used adjusted linear mixed models to
examine the association of the epigenetic age acceleration estimate with fasting and postprandial (0- and 6-h time
points) low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels as well as five
fasting inflammatory markers plus adiponectin.
Results: Both DNA methylation age estimates were highly correlated with chronological age (r > 0.90). We found
that the Horvath and Hannum measures of epigenetic age acceleration were moderately correlated (r = 0.50). The
regression models revealed that the Horvath age acceleration measure exhibited marginal associations with
increased postprandial HDL (p = 0.05), increased postprandial total cholesterol (p = 0.06), and decreased soluble
interleukin 2 receptor subunit alpha (IL2sRα, p = 0.02). The Hannum measure of epigenetic age acceleration
was inversely associated with fasting HDL (p = 0.02) and positively associated with postprandial TG (p = 0.02),
interleukin-6 (IL6, p = 0.007), C-reactive protein (C-reactive protein, p = 0.0001), and tumor necrosis factor alpha
(TNFα, p = 0.0001). Overall, the observed effect sizes were small and the association of the Hannum residual
with inflammatory markers was attenuated by adjustment for estimated T cell type percentages.
Conclusions: Our study demonstrates that epigenetic age acceleration in blood relates to inflammatory biomarkers
and certain lipid classes in Caucasian individuals of the GOLDN study. Future studies should consider epigenetic age
acceleration in other tissues and extend the analysis to other ethnic groups.
Keywords: Epigenetics, Epigenetic age, Age acceleration, Inflammation, Inflammatory markers, Lipids, Postprandial,
Cholesterol, Triglycerides, Adiponectin
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Background
Increasing age is a major risk factor for chronic disease.
Understanding risk factors for accelerated aging can help
target strategies aimed at preventing or delaying onset of
age-related disease [1, 2]. Importantly, the epigenome is
an intriguing target for age-related physiological changes,
as it is modifiable by the environment and is a major de-
terminant of gene expression [3]. Recently, calculated
“epigenetic age” has become a novel aging biomarker,
which has been demonstrated to accurately predict
chronological age across a broad spectrum of tissues and
cell types [4]. Epigenetic age acceleration—or older epi-
genetic age in comparison to chronological age—has been
robustly associated with all-cause mortality [5], obesity
[6], physical fitness [7], and stress [8]. However, acceler-
ated epigenetic aging has not been evaluated in relation to
intermediate phenotypes such as postprandial blood lipid
levels, inflammatory markers, or adiponectin.
Of those, postprandial blood lipid levels are especially
relevant given that most people spend the majority of
the day in a postprandial state [9]. Results from basic
and clinical studies suggest elevated and prolonged post-
prandial lipemia is associated with prothrombotic and
proinflammatory processes that may precipitate cardio-
vascular disease (CVD) and aging [10, 11]. In the current
study, we evaluated the association of two measures of
epigenetic age acceleration [4, 12] with fasting and post-
prandial lipids, five inflammatory markers, and adipo-
nectin, using data from the Genetics of Lipid Lowering
Drugs and Diet Network (GOLDN) study.
Methods
Study population
The GOLDN study determined genetic predictors of
participant lipid and inflammatory response to diet and
fenofibrate treatment interventions [13–15]. Participants
were identified through 3-generation families previously
screened in the National Heart, Lung and Blood Insti-
tute Family Heart Study (FHS) Minnesota and Utah cen-
ters. Individuals who used lipid-lowering drugs at the
time of screening were required to discontinue them for
4 weeks prior to study participation. Participants fasted
for at least 8 h and abstained from alcohol intake for ≥
24 h. The postprandial lipemia intervention followed the
protocol of Patsch et al. [16]. The whipping cream (83%
fat) meal had 700 calories/m2 body surface area; 3% of
calories were derived from protein, and 14% from
carbohydrate. Blood samples were drawn immediately
before the meal with the last draw being 6 h later.
During the 6-h study period, participants consumed only
water and abstained from physical activity. Inflammatory
markers and adiponectin were assayed only in the fast-
ing state. The data used in this analysis were collected at
the time of the postprandial lipemia challenge and, thus,
except for the 6-h lipid measures, was cross-sectional.
Lipids, inflammatory markers, and adiponectin
Triglycerides (TG), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), and total cholesterol were mea-
sured by nuclear magnetic resonance (NMR) spectroscopy
at fasting and during the postprandial intervention
(Liposcience, Raleigh, NC) [17]. High-sensitivity C-reactive
protein (hsCRP) was measured on the Hitachi 911
using a latex particle-enhanced immunoturbidimetric
assay (Kamiya Biomedical Company, Seattle, WA).
Interleukin-6 (IL6), interleukin-2 soluble receptor
alpha (IL2sRα), tumor necrosis factor (TNF)-α and
monocyte chemoattractant protein-1 (MCP1) were mea-
sured using quantitative sandwich enzyme immunoassays
(ELISA kit assays, R&D Systems Inc., Minneapolis, MN)
as described in previous publications [18, 19]. Adiponectin
was measured using an ELISA kit from R&D Systems
(Minneapolis, MN) [20].
DNA methylation measurements and epigenetic age
calculation
DNA from a total 993 GOLDN participants was assayed
using Illumina’s Infinium HumanMethylation450 Bead-
chip as previously described by Irvin et al. [21]. Briefly,
CD4+ T cells were harvested from stored buffy coats
(from the fasting sample) using antibody-linked Invitro-
gen Dynabeads [22]. Cells were lysed and DNA was ex-
tracted using DNeasy kits (Qiagen, Venlo, Netherlands).
After following standard Illumina protocols, the
resulting intensity files were analyzed with Illumina’s
GenomeStudio to generate beta scores representing
the percent of methylated sites at that location across
all the cells in a sample. After previously reported
QC, methylation data were available for 461,281 5′-
cytosine-phosphate-guanine-3′ genomic site (CpGs)
[21]. The non-normalized data were uploaded into
the DNA methylation age calculator [4] using the ad-
vanced analysis in blood option. We removed 140
samples for which the predicted tissue was not blood.
To err on the side of caution, we removed 23 individ-
uals from the analysis because they were severe out-
liers according to the Horvath measure of epigenetic
age acceleration (> 4 standard deviations away from
the mean), leaving a total sample size of n = 830 indi-
viduals for the analysis.
In addition to the Horvath measure of epigenetic age
acceleration, we considered another independent meas-
ure of age acceleration derived from the Hannum
methylation age estimate [12]. Both methylation age ac-
celeration estimates have been associated with outcomes
in a side-by-side manner in previous publications [5, 23,
24]. The Horvath methylation age estimate (DNAm age)
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is based on 353 CpGs and has been robustly correlated
with chronological age in multiple studies. DNAm age
sometimes systematically underestimates chronological
age [25]. To remove this systematic offset from the ana-
lysis, this study leverages epigenetic age acceleration de-
fined by regressing DNAm age on chronological age and
forming residuals. The second estimate is based on Han-
num’s methylation age estimate calculated from 71
CpGs. Figures 1 and 2 are the scatter plots of calculated
epigenetic age versus chronological age for the Horvath
and Hannum calculators, respectively, in GOLDN. The
Horvath and the Hannum measures of DNAm age are
related, but they capture slightly different aspects of
biology (only 6 CpGs overlap) [5]. The Hannum age esti-
mator is correlated with estimated blood cell counts,
which reflects that it was constructed on the basis of
whole blood DNA methylation data [5, 26]. In the
current analysis, we focused on a modification of the
Hannum estimate described (in previous publications) as
extrinsic epigenetic age acceleration (EEAA) since it has
been found to outperform the original Hannum measure
when it comes to predicting lifespan [5]. EEAA is a re-
sidual formed from regressing the Hannum estimate
weighted by the proportion of naive CD8+ T cells,
exhausted CD8+ T cells, and plasmablasts on chrono-
logical age which makes the estimate more strongly re-
flective of immune system aging [5, 23, 27]. Chen et al.
reported the Hannum estimator tracks aspects of immu-
nosenescence exhibiting significant (albeit weak) correla-
tions with several markers of immunosenescence, e.g.,
the abundance of senescent (or conversely naïve) T cells
and telomere length [26, 27]. The Horvath DNAm age
estimator exhibits substantially weaker correlations with
estimated blood cell counts, which reflects the fact that
it was constructed across a broad spectrum of tissues
and cell types. Overall, the Horvath DNAm age estima-
tor does not relate to measures of immunosenescence
(including telomere length) [27]. Rather, it mostly cap-
tures cell intrinsic DNAm age changes which might re-
flect the actions of an innate aging process.
For both methylation age acceleration estimates, a
positive value indicates that the epigenetic age is higher
than expected based on chronological age (i.e., acceler-
ated epigenetic aging). We note EEAA in GOLDN is
limited by the use of DNA methylation data derived
from CD4+ T cells as opposed to peripheral blood
mononuclear cells (PBMCs) like in previous studies. For
a more direct comparison to the Horvath estimate we
also report the results for the Hannum residual defined
by regressing the (unweighted) Hannum methylation age
estimate on chronological age in a secondary analysis.
Statistical analysis
Participant characteristics were compared by the median
of each age acceleration measure using chi square tests
and t-tests, as appropriate. TG, hsCRP, IL6, IL2sRα, TNFα,
MCP1, and adiponectin were ln-transformed to achieve
normality. Pearson correlation coefficients between lipids,
inflammatory markers, adiponectin, and each measure of
age acceleration were also estimated. We used linear
mixed models to examine the association of the Horvath
epigenetic age acceleration residual with fasting and post-
prandial total cholesterol, LDL, HDL, and TG as well as
inflammatory markers and adiponectin (as outcomes).
Fig. 1 Calculated (Horvath method) epigenetic age versus chronological
age in GOLDN
Fig. 2 Calculated (Hannum method) epigenetic age versus
chronological age in GOLDN
Irvin et al. Clinical Epigenetics  (2018) 10:56 Page 3 of 9
The model was adjusted for age, study site, sex, corre-
sponding fasting lipid level (if applicable), deconvolution
estimated T cell type (naïve, regulatory, memory) percent-
ages (estimated using a method developed by the GOLDN
group [28]), age acceleration estimate squared (to account
for a potential non-linear effect of this variable), current
smoking status, current drinking status and a random ef-
fect of family relationship. Linear mixed models were im-
plemented in the R kinship package (lmekin function)
[29]. For our analysis of the EEAA estimate we used a
similar model, except the model was not adjusted for esti-
mated T cell type percentages since blood cell compos-
ition is a component of the age acceleration estimate. For
both the Horvath and Hannum estimates we considered a
sensitivity model adjusted for history of coronary heart
disease (CHD) and diabetes status. Further, we explored a
gender by age acceleration interaction term. In total we
tested the association of 14 outcomes with each age accel-
eration estimate making the Bonferroni correction for
multiple testing p = 0.003 (0.05/14). In secondary ana-
lysis we examined the association of each outcome
with the Hannum residual, considering the model
described above for EEAA both with and without
adjustment for T cell percentages.
Results
The mean and standard deviation of the Horvath and
Hannum (EEAA) estimates were − 3.54 (6.1) and − 1.32
(8.3), respectively. The Pearson correlation coefficient
between methylation and chronological age was 0.94 (p
< 0.0001) for the Horvath estimate and 0.91 (p < 0.0001)
for the Hannum (EEAA) estimate. The correlation coef-
ficient between the Horvath and Hannum (EEAA) age
acceleration measures was 0.50 (p < 0.0001). Table 1
shows descriptive statistics of the GOLDN population,
categorized by the median of each age acceleration value
(− 3.33 and − 1.64 for the Horvath and Hannum (EEAA)
estimates, respectively). There was a higher prevalence
Table 1 Descriptive statistics of the GOLDN study population categorized by the median of two age acceleration residuals
Horvath age acceleration Hannum age acceleration (EEAA)
N (%) or mean (SD) Below median Above median p Below median Above median p
Center (UT) 220 (53.0) 153 (36.9) < 0.0001 223 (46.2) 192 (43.6) 0.44
Female 226 (54.5) 193 (46.5) 0.02 222 (53.5) 197 (47.5) 0.08
Current smoker 34 (8.2) 35(8.4) 0.89 32 (7.7) 37 (8.9) 0.52
Current drinking 201 (48.4) 238 (57.4) 0.01 228(54.9) 211 (50.8) 0.23
History of CHD 16 (3.9) 27 (6.5) 0.08 15 (3.6) 28 (6.8) 0.04
Hypertension 99 (23.9) 121 (29.2) 0.08 89 (21.5) 131 (31.6) 0.001
Diabetes 22 (5.3) 41 (9.8) 0.01 23 (5.5) 40 (9.6) 0.03
Age 46.6 (16.2) 50.7 (15.5) 0.0002 46.6 (16.1) 50.7 (15.6) 0.0002
Lipids
LDL mg/dL (0 h) 114.9 (31.8) 121.7 (32.2) 0.003 116.5 (31.8) 120.1 (32.4) 0.10
LDL mg/dL (6 h) 119.2(32.1) 125.9 (33.2) 0.003 120.8 (32.2) 124.4 (33.3) 0.12
HDL mg/dL (0 h) 46.0 (14.1) 44.5 (13.1) 0.12 47.1 (14.5) 43.4 (12.4) < 0.0001
HDL mg/dL (6 h) 48.8 (14.6) 47.8 (14.1) 0.34 50.2 (15.2) 46.3 (133) < 0.0001
TC mg/dL (0 h) 181.6 (38.4) 189.7 (40.0) 0.003 183.9 (38.8) 187.4(39.9) 0.20
TC mg/dL (6 h) 189.2 (39.6) 199.0 (42.9) 0.0007 191.9 (40.3) 196.3 (42.7) 0.13
TG mg/dL (0 h) 135.5 (84.8) 155.5 (108.5) 0.003 133.4 (83.0) 157.8 (109.5) 0.0003
TG mg/dL (6 h) 187.9 (130.5) 230.8 (166.8) < 0.0001 187.0 (129.7) 231.8 (167.3) < 0.0001
Inflammatory markers
IL6 1.9 (2.2) 2.2 (4.4) 0.11 1.8 (26) 2.2 (4.2) 0.08
CRP 0.21 (0.3) 0.25 (0.4) 0.22 0.20 (0.4) 0.26 (0.4) 0.03
MCP1 207.8 (62.5) 211.2 (68.7) 0.45 204.3 (64.9) 214.7 (66.1) 0.02
IL2SRA 1012.3 (344.5) 1021.2 (377.1) 0.72 991.2 (330.3) 1042.3 (388.0) 0.04
Adiponectin 8498.6 (4644.7) 8047.9 (4827.6) 0.17 8568.1 (4746.8) 7978.2 (4719.4) 0.07
TNFα 3.2 (1.9) 3.9 (8.0) 0.08 3.1 (1.8) 4.0 (8.0) 0.02
EEAA extrinsic epigenetic age acceleration, CHD coronary heart disease, CRP C-reactive protein, DNAmage DNA methylation age, HDL high-density lipoprotein,
IL2SRA interleukin-2 soluble receptor alpha, IL6 interleukin 6, LDL low-density lipoprotein, MCP1 monocyte chemotactic protein 1, TC total cholesterol, TG triglyceride,
TNFa tumor necrosis factor alpha
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of current drinking, history of CVD, hypertension, and
diabetes associated with being above the median for the
Horvath age acceleration measure. Similarly, being above
the median of the age acceleration estimate for the Han-
num method was associated with history of CVD, hyper-
tension, and diabetes, but not with current drinking.
Increasing age acceleration as measured by the Horvath
method was associated with increased LDL, TC, and TG
in the fasting and postprandial states. Having an age ac-
celeration estimate above the median for the Hannum
method was associated with decreased HDL and in-
creased TG in the fasting and postprandial states. The
Hannum measure of age acceleration (but not the Hor-
vath measure) was also associated with increased C-
reactive protein (CRP), IL2sRα, tumor necrosis factor
alpha (TNFα), and MCP1 (Table 1). Table 2 shows the un-
adjusted correlation coefficients for each age acceleration
estimate with lipid classes, inflammatory markers, and adi-
ponectin. Each age acceleration measure was associated
with lipid classes in the fasting and postprandial state ex-
cept the Horvath measure was not associated with HDL.
Each measure of age acceleration was inversely associated
with adiponectin. The Hannum age acceleration estimate
but not the Horvath estimate was positively associated
with more than one inflammatory marker.
Regression results for the Horvath and Hannum age
acceleration estimates are presented in Table 3. The
Horvath epigenetic age acceleration residual was not as-
sociated with fasting lipid levels. Increasing age acceler-
ation residual was marginally associated with higher
postprandial HDL (p = 0.05) and postprandial total choles-
terol (p = 0.06) after adjustment. The effect size for these
associations is 0.30 mg/dL and 0.92 mg/dL for postprandial
HDL and TC respectively for each 1 standard deviation
change in the age acceleration estimate. The Horvath age
acceleration estimate was also inversely associated (albeit
marginally) with IL2sRα. The Hannum EEAA measure was
inversely associated with fasting (p = 0.02) but not post-
prandial HDL levels, and was positively associated with
postprandial (p = 0.02) but not fasting TG. The Hannum
measure of epigenetic age acceleration was also strongly
positively associated with IL6 (p = 0.007), CRP (p = 0.0001),
and TNFα (p = 0.0001). The association of EEAA with CRP
and TNFα were the only two associations that reached stat-
istical significance after correction for multiple testing in
Table 3. The ratio of postprandial TG, IL6, CRP, and TNFα
associated with each 1 standard deviation increase in EEAA
was 1.03, 1.06, 1.16, and 1.06, respectively. Additionally,
adjusting for history of CHD and diabetes status in these
models did not substantially change our results (data not
shown). We did not find evidence of effect modification by
gender of the relationship between epigenetic age acceler-
ation and our traits except for CRP, where CRP was associ-
ated with epigenetic age acceleration (EEAA estimate) only
in females (p = 0.048). This result does not pass significance
criteria after correction for multiple testing.
In secondary analysis of the Hannum residual (Table 4),
the results were consistent with those presented for EEAA
in Table 3 except that the Hannum residual was not
associated with IL6. After T cell type percentages were
Table 2 Marginal correlations between lipid and other biomarkers with epigenetic age acceleration in the GOLDN study
Horvath age acceleration Hannum age acceleration (EEAA)
r p r p
Lipids
LDL mg/dL (0 h) 0.11 0.0008 0.11 0.002
LDL mg/dL (6 h) 0.12 0.0009 0.10 0.003
HDL mg/dL (0 h) − 0.02 0.50 − 0.13 0.0002
HDL mg/dL (6 h) − 0.01 0.83 − 0.12 0.0004
TC mg/dL (0 h) 0.12 0.0004 0.08 0.02
TC mg/dL (6 h) 0.14 < .0001 0.09 0.007
TG mg/dL (0 h) 0.11 0.001 0.11 0.002
TG mg/dL (6 h) 0.17 < .0001 0.15 < .0001
Inflammatory markers
IL6 (0 h) 0.05 0.18 0.09 0.02
CRP (0 h) 0.04 0.25 0.06 0.09
MCP1 (0 h) 0.01 0.81 0.07 0.05
IL2SRA (0 h) −0.01 0.84 0.08 0.01
Adiponectin (0 h) − 0.08 0.03 − 0.07 0.05
TNFα (0 h) 0.05 0.16 0.11 0.002
EEAA extrinsic epigenetic age acceleration, 0 h fasting time point, 6 h postprandial time point
Irvin et al. Clinical Epigenetics  (2018) 10:56 Page 5 of 9
included in the model, the association with fasting HDL,
CRP, and TNFα was attenuated. Postprandial TG
remained marginally (0.08) associated with the Hannum
residual even after adjustment for T cell type percentages.
Discussion
Measures of epigenetic age acceleration are robust bio-
markers of aging independent of chronological age [4, 12].
In the current study, we tested the association of two dif-
ferent measures of epigenetic age acceleration with meta-
bolic and inflammatory markers in 830 Genetics Of Lipid
Lowering Drugs and Diet Network study participants.
Similar to previous publications, epigenetic age acceler-
ation was marginally associated with lipids, including
postprandial lipids. We are the first to report that a meas-
ure of epigenetic age acceleration derived from the Han-
num methylation age estimate (referred to as extrinsic
epigenetic age acceleration) was strongly related to more
than one inflammatory marker. However, further analysis
showed this relationship was not independent of T cell
type composition. Previous studies have reported each
epigenetic age acceleration measure to be associated with
outcomes including cancer mortality, cardiovascular dis-
ease mortality, and all-cause mortality [5, 30]. Continued
research is needed to better understand if increased in-
flammation could be a pathway through which epigenetic
aging is related to these outcomes.
A recent large meta-analysis of over 13,000 partici-
pants (including non-Hispanic whites, Hispanics, and
African Americans) demonstrated that, independent of
chronological age and traditional risk factors, epigenetic
age acceleration assessed in blood (measured by both
the Horvath and Hannum methods) predicted all-cause
mortality [5]. Another study of ~ 2000 older Caucasian
individuals from the ESTHER cohort (a large
population-based epidemiologic study of chronic disease
in Germany) reported that, for each 5 year increase of
DNA methylation age (DNAmage, Horvath estimate)
minus chronological age, the hazard ratio for all-cause
mortality was 1.23 (95% CI 1.10–1.38), cancer mortality
was 1.22 (95% CI 1.03–1.45), and cardiovascular mortal-
ity was 1.19 (95% CI 0.98–1.43) after adjustment for
confounding factors [30]. Among ~ 1500 women from
the Women’s Health Initiative (WHI) study in a report
from Horvath et al., neither measure of epigenetic age ac-
celeration was associated with coronary heart disease
(CHD) [24]. In that study, the measure of epigenetic age
acceleration derived from the Horvath calculator was not
robustly associated with triglyceride levels, HDL, glucose,
CRP, or body mass index (BMI, p > 0.05) after adjustment.
The extrinsic epigenetic age acceleration estimate (Han-
num) was associated with fasting TG (p = 0.04) and CRP
(p = 0.02), but not fasting HDL (p = 0.80). In our study,
the direction of association of the Horvath estimate with
Table 3 Multivariable linear regression models that relate biomarkers (rows) to epigenetic age acceleration (covariate) using the
Horvath calculator and the Hannum calculator
Horvath age acceleration Hannum age acceleration (EEAA)
Dependent variable Beta* SE p Beta# SE p
LDL mg/dL (0 h) 0.36 0.21 0.09 0.166 0.12 0.17
LDL mg/dL (6 h) 0.003 0.06 0.96 − 0.006 0.04 0.87
HDL mg/dL (0 h) 0.06 0.08 0.52 − 0.11 0.04 0.02
HDL mg/dL (6 h) 0.05 0.03 0.05 0.004 0.15 0.81
TC mg/dL (0 h) 0.44 0.25 0.08 0.091 0.14 0.52
TC mg/dL (6 h) 0.15 0.08 0.06 0.068 0.05 0.13
TG mg/dL (0 h) 0.001 0.004 0.75 0.002 0.002 0.30
TG mg/dL (6 h) 0.0005 0.002 0.84 0.004 0.001 0.02
IL6 (0 h) − 0.001 0.004 0.76 0.007 0.002 0.007
CRP (0 h) 0.007 0.008 0.34 0.018 0.004 0.0001
MCP1 (0 h) − 0.001 0.002 0.55 − 0.0003 0.001 0.76
IL2SRA(0 h) − 0.006 0.002 0.02 0.002 0.001 0.09
Adiponectin (0 h) − 0.003 0.004 0.46 − 0.003 0.002 0.24
TNFα (0 h) − 0.0008 0.003 0.80 0.007 0.002 0.0001
Since the models include a quadratic term the effect of a one unit change in x on y is not constant
EEAA extrinsic epigenetic age acceleration, 0 h fasting time point, 6 h postprandial time point, CRP C-reactive protein, HDL high-density lipoprotein, IL2SRA
interleukin-2 soluble receptor alpha, IL6 interleukin-6, LDL low-density lipoprotein, MCP1 monocyte chemotactic protein 1, SE standard error, TC total cholesterol,
TG triglyceride, TNFa tumor necrosis factor alpha
*Model is adjusted for adjusted for age, study site, sex, fasting lipid level (if applicable), estimated T cell type percentages, epigenetic age acceleration estimate
squared (i.e., a quadratic polynomial), current smoking status, current drinking status, and a random effect of family relationship
#Model is adjusted for adjusted for age, study site, sex, fasting lipid level (if applicable), epigenetic age acceleration estimate squared (i.e., a quadratic polynomial),
current smoking status, current drinking status, and a random effect of family relationship
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fasting HDL was positive (p = 0.52), while the Hannum
EEAA estimate was negatively associated with fasting
HDL (p = 0.02). In the report from Horvath et al. men-
tioned above, the direction of association for the Horvath
and Hannum estimates with HDL also conflicted. Another
study reported that older epigenetic age in comparison to
chronological age was associated with increased BMI in
middle-aged but not in older adults, suggesting that the
relationship between age acceleration and metabolic traits
may change over the lifespan [6].
Since elevated postprandial lipids are predictive of
aging and inflammation [9, 10], we investigated whether
epigenetic age acceleration was associated with post-
prandial lipids. Like fasting lipids and other cardiometa-
bolic risk factors investigated in other studies, our
results demonstrate that epigenetic age acceleration is a
modest predictor of postprandial lipemia. None of the
results for lipids presented in Table 3 (fasting or post-
prandial) were significant after correction for multiple
testing. Notably, after adjustment EEAA was associated
with higher levels of postprandial TGs (p = 0.02), which
is the lipid class that changes the most upon fat loading.
The Horvath measure of epigenetic age acceleration was
marginally associated with higher postprandial TC. With
PPL and methylation measured on a single day in
GOLDN, it is difficult to determine if increased meta-
bolic parameters could lead to accelerated epigenetic age
or vice versa. Longitudinal PPL and methylation data
would be necessary to untangle the temporal relation-
ship between epigenetic age acceleration and postpran-
dial lipids. Few other studies have investigated whether
diet is linked to epigenetic age acceleration. One study
including > 4000 postmenopausal female participants
from the WHI, as well as 402 male and female partici-
pants from the Italian cohort study, Invecchiare nel
Chianti, suggested poultry intake was protective for epi-
genetic aging. In that same study, fish intake, alcohol,
and smoking were not associated with the epigenetic age
acceleration residual as measured by the Horvath age
calculator.
In GOLDN, the epigenetic age acceleration measure
from Horvath’s calculator was associated with IL2sRα
but not other inflammatory markers or adiponectin. On
the other hand, EEAA was positively (but modestly) as-
sociated with three biomarkers of inflammation (IL6,
CRP, and TNFα). Elevation of these three markers has
been associated with a number of age-related chronic
diseases [31]. Additionally, we considered the Hannum
residual in a secondary analysis to help understand if the
association between EEAA and inflammatory markers
observed in our primary analysis could be due to a dif-
ference in probes across the two age acceleration mea-
sures or a function of the contribution of blood cell
composition to the Hannum EEAA estimate. After ad-
justment for T cell type composition in a model consid-
ering the Hannum residual as the variable of interest,
the three inflammatory markers were no longer associ-
ated with the Hannum estimate. In a previous study,
EEAA was shown to be correlated with the sample esti-
mated naïve and memory CD8+ T cell populations [27].
In that same study, adjustment for T cell composition in a
model correlating EEAA to leukocyte telomere length
attenuated the association. In our study, the Hannum
residual and Hannum EEAA estimate were strongly
correlated with estimated populations of naïve CD4+ T cell
percentages (r = − 0.45, p < 0.0001 and − 0.62, p < 0.0001,
respectively). Overall, this lends further support to the
conclusions from Chen et al. which suggested that EEAA
captures information on key aspects of immunosenescence,
which may help explain the stronger relationship of EEAA
with mortality observed in a previous study in comparison
to the Horvath estimate [5].
The current study is set in one of few observational
epidemiology cohort studies with epigenetic array data
and a postprandial lipemia intervention on a sizable
population. Participants in the GOLDN study are, on
Table 4 Multivariable linear regression models that relate
biomarkers (rows) to epigenetic age acceleration (covariate) using
the Hannum residual with and without adjustment for estimated
T cell type percentages
Hannum residual
Model 1 Model 2
Dependent variable Beta SE p Beta SE p
LDL mg/dL (0 h) 0.12 0.14 0.39 0.12 0.15 0.41
LDL mg/dL (6 h) 0.003 0.04 0.94 0.02 0.05 0.71
HDL mg/dL (0 h) − 0.12 0.05 0.03 − 0.06 0.06 0.32
HDL mg/dL (6 h) 0.002 0.02 0.91 0.0008 0.02 0.97
TC mg/dL (0 h) 0.08 0.16 0.60 0.10 0.17 0.56
TC mg/dL (6 h) 0.07 0.05 0.16 0.07 0.05 0.17
TG mg/dL (0 h) 0.004 0.002 0.10 0.003 0.003 0.23
TG mg/dL (6 h) 0.003 0.002 0.03 0.003 0.002 0.08
IL6 (0 h) 0.002 0.003 0.53 − 0.002 0.003 0.46
CRP (0 h) 0.01 0.005 0.005 0.007 0.006 0.20
MCP1 (0 h) − 0.00008 0.001 0.95 0.0006 0.001 0.62
IL2SRA (0 h) − 0.00006 0.002 0.97 − 0.0004 0.002 0.79
Adiponectin (0 h) − 0.003 0.002 0.20 − 0.0010 0.003 0.72
TNFα (0 h) 0.004 0.002 0.04 0.002 0.002 0.37
Model 1 is adjusted for adjusted for age, study site, sex, fasting lipid level (if
applicable), epigenetic age acceleration estimate squared (i.e., a quadratic
polynomial), current smoking status, current drinking status, and a random
effect of family relationship. Model 2 adds estimated T cell type percentages
to model 1. Since the models include a quadratic term, the effect of a one unit
change in x on y is not constant
0 h fasting time point, 6 h postprandial time point, CRP C-reactive protein, HDL
high-density lipoprotein, IL2SRA interleukin-2 soluble receptor alpha, IL6 interleukin
6, LDL low-density lipoprotein, MCP1 monocyte chemotactic protein 1, SE standard
error, TC total cholesterol, TG triglyceride, TNFa tumor necrosis factor alpha
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average, middle aged, and because the study required
discontinuation of lipid-lowering therapy, the study
population is relatively healthy. Studies of the relation-
ship between postprandial lipemia and epigenetic aging
are still warranted in other groups (e.g., older individ-
uals, other ethnic groups) and in other tissues.
Conclusion
Inflammatory markers associated with aging exhibit
significant associations with a measure of epigenetic age
acceleration. However, this association was not inde-
pendent of other key aspects of immune system aging
(estimated naïve T cell type percentages) in our study.
The same measure of epigenetic age acceleration was
weakly associated with increased postprandial triglycer-
ide levels. Future studies should revisit these analyses by
employing even larger sample sizes, different ethnic
groups, and DNA methylation data from other tissues,
such as saliva, which may be easier to collect.
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